Women's Health & Pregnancy Clinical Trials

Statistical methods in women's health & pregnancy trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All women's health & pregnancy trials

490 results

• A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002): Complete Statistical AnalysisIndependent statistical analysis of A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 3,074NCT00943722
• A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006): Complete Statistical AnalysisIndependent statistical analysis of A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006): primary endpoint results, effect estimate with…Phase 3Results postedn = 924NCT01047345
• A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission: Complete Statistical AnalysisIndependent statistical analysis of A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission: primary endpoint results, effect estimate…Phase 2Results postedn = 104NCT00739661
• A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 109NCT00121836
• A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 48NCT04424641
• A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function: Complete Statistical AnalysisIndependent statistical analysis of A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 397NCT00478881
• A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.: Complete Statistical AnalysisIndependent statistical analysis of A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.: primary endpoint results, effect…Phase 2Results postedn = 16NCT00678288
• A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703): Complete Statistical AnalysisIndependent statistical analysis of A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm…Phase 3Results postedn = 259NCT00725491
• A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 178NCT02202746
• A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.: Complete Statistical AnalysisIndependent statistical analysis of A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 558NCT05338086
• A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer: primary endpoint…Phase 3Results postedn = 596NCT00950300
• A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic…Phase 3Results postedn = 369NCT01160211
• A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 11NCT03343067
• A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD): Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD): primary endpoint…Phase 3Results postedn = 2NCT04064827
• A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 2,858NCT01178125
• A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 25NCT03116685
• A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer: primary endpoint results, effect…Phase 3Results postedn = 49NCT02144012
• A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787): Complete Statistical AnalysisIndependent statistical analysis of A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as…Phase 3Results postedn = 1,509NCT00696800
• A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease: primary endpoint results,…Phase 2Results postedn = 714NCT05182840
• A Trial of FANG™ Vaccine for Participants With Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Trial of FANG™ Vaccine for Participants With Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01309230).Phase 2Results postedn = 39NCT01309230
• A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 40NCT01310231
• A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 1NCT03498196
• A-PREDICTIndependent statistical analysis of A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 65NCT01693822
• AASKA statistical analysis of the AASK phase 3 trial evaluating blood pressure targets and antihypertensive strategies in African American patients with hypertensive nephrosclerosis and chronic renal insufficiency.Phase 3n = 1,094NCT04364139
• ABEMA Alone or in COMBO With MK-6482: Complete Statistical AnalysisIndependent statistical analysis of ABEMA Alone or in COMBO With MK-6482: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04627064).Phase 1Results postedn = 11NCT04627064
• ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 50NCT00394082
• Accupressure of P6 to Reduce Nausea During Cesarean Section: Complete Statistical AnalysisIndependent statistical analysis of Accupressure of P6 to Reduce Nausea During Cesarean Section: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04799587).Phase NAResults postedn = 200NCT04799587
• ACTG 076Independent statistical analysis of ACTG 076, a phase 3 study of zidovudine in HIV-infected pregnant women and their infants, including trial design, statistical methodology, planned analysis, limitations, and interpretation.Phase 3n = 1,496NCT00000960
• Acupressure for Fatigue in Ovarian Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Acupressure for Fatigue in Ovarian Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03763838).Phase NAResults postedn = 171NCT03763838
• Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial: Complete Statistical AnalysisIndependent statistical analysis of Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 22NCT02232282
• Acute Exercise Effects in Obese Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Acute Exercise Effects in Obese Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03750695).Phase NAResults postedn = 16NCT03750695
• Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda: Complete Statistical AnalysisIndependent statistical analysis of Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 440NCT00405821
• ADAPTIndependent statistical analysis of Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 250NCT02306265
• Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study: Complete Statistical AnalysisIndependent statistical analysis of Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03624972).Phase NAResults postedn = 153NCT03624972
• ADORE BRAINIndependent statistical analysis of Brain Health in Midlife: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06640842).Phase NAResults postedn = 24NCT06640842
• Afatinib in Subjects With Kidney Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Afatinib in Subjects With Kidney Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02096718).Phase 1Results postedn = 30NCT02096718
• AiME – 13Independent statistical analysis of A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance…Phase 3Results postedn = 320NCT01473420
• AKIKIIndependent statistical analysis of AKIKI (NCT01932190), a randomized trial comparing early and delayed renal replacement therapy strategies in intensive care patients with acute kidney injury.Phase NAn = 620NCT01932190
• Alcohol and Breast Cancer (ABC) Trial: Complete Statistical AnalysisIndependent statistical analysis of Alcohol and Breast Cancer (ABC) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05423730).Phase NAResults postedn = 23NCT05423730
• Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1Results postedn = 15NCT00702299
• Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer: primary endpoint…Phase 2Results postedn = 191NCT01091428
• Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1/2Results postedn = 273NCT01045421
• Alkali Therapy in Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Alkali Therapy in Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01452412).Phase 2/3Results postedn = 149NCT01452412
• Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 45NCT01487954
• Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 5NCT00523809
• Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 13NCT01105650
• Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 5NCT00074269
• AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 23NCT00574951
• AMILORIndependent statistical analysis of Amiloride in Nephrotic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05079789).Phase 3Results postedn = 20NCT05079789
• Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04790279).Phase 4Results postedn = 175NCT04790279

← All therapeutic areas